| Methods |
4‐week single‐blind placebo phase; inclusion criteria= DBP 100‐115 mm Hg after placebo phase; 12‐week double‐blind treatment, dosage doubled every 4 weeks (10‐40 mg twice daily) |
| Participants |
Quinapril: n=7(2 males,5 females); mean age=48(11) years; baseline SBP=159(8) mm Hg, DBP=105(3) mm Hg;
Placebo: n=7(3 males,4 females); mean age=47(13) years; baseline SBP=162(21) mm Hg, DBP=105(5) mm Hg |
| Interventions |
Quinapril 10 mg twice daily;
Placebo |
| Outcomes |
Trough (12h after previous dose) sitting SBP/DBP using mercury sphygmomanometer |
| Notes |
Used week 4 BP data only; BP change and SD of change not reported, endpoint BP and SEM reported, calculated endpoint SD from N and endpoint SEM, imputed endpoint SD for SD of change; BP data from Figure 2, p. 90; Jadad score=2; funding source= Warner‐Lambert/Parke‐Davis Co. |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
